Status:
COMPLETED
Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Hepatocellular Carcinoma
Liver Cirrhosis
Eligibility:
All Genders
18-70 years
Brief Summary
Results of liver transplantation, the best theoretical treatment for HCC, are limited by tumor recurrence. In order to limit this risk Milan criteria was proposed in 1996. However, these criteria are ...
Detailed Description
In this study, the investigators studied the predictive value of imaging techniques such as CT, MRI, PET scan, of serological markers and molecular markers assessed before liver transplantation at lis...
Eligibility Criteria
Inclusion
- Liver cirrhosis
- Hepatocellular carcinoma diagnosed by AASLD criteria or liver biopsy
- Listing for Liver transplantation for HCC fulfilling or not Milan criteria
- No extra-hepatic spread
- No vascular involvement
Exclusion
- Salvage transplantation
- Transplantation contra-indication
- Evaluation for Liver transplantation older than 1 month
- Incidental HCC
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2020
Estimated Enrollment :
372 Patients enrolled
Trial Details
Trial ID
NCT01198704
Start Date
January 1 2009
End Date
January 1 2020
Last Update
November 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Universitaire d'Hépato-gastroentérologie
Grenoble, France, 38043